CAR T-cell immunotherapy of B-cell malignancy: the story so far

Leena Halim*, John Maher

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

33 Citations (Scopus)

Abstract

Chimeric antigen receptor (CAR) T-cell immunotherapy has achieved unprecedented efficacy in the treatment of chemotherapy-resistant or refractory B-cell malignancies. Promising results from pivotal anti-CD19 CAR T-cell phase II trials have led to landmark approvals of two CD19-specific CAR T-cell products by the United States Food and Drug Administration and European Medicines Agency. However, several issues associated with CAR T-cell treatment remain unresolved, such as the management of severe toxicities and the frequent occurrence of both antigen-positive and antigen-negative relapse. Nonetheless, pre-clinical research is advancing at an unprecedented pace to develop innovative solutions to address these issues. Herein, we summarise recent clinical developments and outcomes of CD19-targeted CAR T-cell immunotherapy and discuss emerging strategies that may further improve the success, safety and broadened applicability of this approach.

Original languageEnglish
JournalTherapeutic Advances in Vaccines and Immunotherapy
Volume8
DOIs
Publication statusPublished - 2020

Keywords

  • B-cell
  • CD19
  • chimeric antigen receptor
  • clinical trial
  • leukaemia
  • lymphoma

Fingerprint

Dive into the research topics of 'CAR T-cell immunotherapy of B-cell malignancy: the story so far'. Together they form a unique fingerprint.

Cite this